Jun 4 |
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
|
Jun 4 |
Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
|
Jun 3 |
Why Is German Biotech Affimed Stock Soaring On Monday?
|
Jun 1 |
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
|
May 29 |
Affimed gets FDA fast track status for AFM24 for EGFR lung cancer
|
May 29 |
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
|
May 28 |
Affimed Announces Annual General Meeting of Shareholders
|
May 28 |
7 Penny Biotech Stocks to Triple Your Investment
|
May 23 |
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
|
May 17 |
Small-Cap Sensations: 3 Stocks Under $10 With 10X Potential
|